Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass

✍ Scribed by B. Keymeulen; M. Walter; C. Mathieu; L. Kaufman; F. Gorus; R. Hilbrands; E. Vandemeulebroucke; U. Van de Velde; L. Crenier; C. De Block; S. Candon; H. Waldmann; A. G. Ziegler; L. Chatenoud; D. Pipeleers

• Publisher: Springer
• Year: 2010
• Tongue: English
• Weight: 216 KB
• Volume: 53
• Category: Article
• ISSN: 0012-186X
• DOI: 10.1007/s00125-009-1644-9